Hills Bank & Trust Co. Purchases 1,120 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Hills Bank & Trust Co. increased its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 13.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,295 shares of the biopharmaceutical company’s stock after purchasing an additional 1,120 shares during the period. Hills Bank & Trust Co.’s holdings in Alexion Pharmaceuticals were worth $1,256,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Captrust Financial Advisors purchased a new stake in shares of Alexion Pharmaceuticals in the 4th quarter valued at approximately $31,000. NuWave Investment Management LLC increased its position in shares of Alexion Pharmaceuticals by 851.9% in the 4th quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 460 shares during the last quarter. Kaizen Advisory LLC increased its position in shares of Alexion Pharmaceuticals by 22.2% in the 4th quarter. Kaizen Advisory LLC now owns 610 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 111 shares during the last quarter. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Alexion Pharmaceuticals in the 4th quarter valued at approximately $68,000. Finally, Prime Capital Investment Advisors LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 1st quarter valued at approximately $74,000. 94.79% of the stock is owned by hedge funds and other institutional investors.

Shares of ALXN stock opened at $131.77 on Friday. The company has a market cap of $29.55 billion, a price-to-earnings ratio of 18.59, a price-to-earnings-growth ratio of 1.08 and a beta of 1.53. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.36 and a current ratio of 3.87. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $92.56 and a fifty-two week high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.40. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. Alexion Pharmaceuticals’s revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.68 earnings per share. As a group, equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 8.6 earnings per share for the current fiscal year.

Several research analysts have recently issued reports on the stock. Raymond James started coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, April 10th. They issued an “outperform” rating and a $161.00 target price for the company. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Royal Bank of Canada restated an “outperform” rating and issued a $186.00 target price (up previously from $165.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 27th. Cowen restated a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 13th. Finally, TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a report on Thursday, April 25th. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $162.25.

In other news, CAO Daniel Bazarko sold 2,000 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Thursday, February 14th. The shares were sold at an average price of $126.00, for a total transaction of $252,000.00. Following the sale, the chief accounting officer now owns 5,020 shares in the company, valued at $632,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.08% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Hills Bank & Trust Co. Purchases 1,120 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/alexion-pharmaceuticals-inc-alxn-shares-bought-by-hills-bank-trust-co.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: Terms to Better Understand Call Options

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.